Results 131 to 140 of about 2,368 (193)

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. [PDF]

Vaccines (Basel)
Paes BA, Manzoni P, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X.   +4 more
europepmc   +1 more source

Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status. [PDF]

Vaccines (Basel)
Ladomenou F, Psarra IA, Gkentzi D.
europepmc   +1 more source

Early impact of maternal RSV vaccination on bronchiolitis hospitalisation and critical care admissions in infants under age 3 months, England, September 2024 to March 2026. [PDF]

Euro Surveill
Broad J, Wilson M, Borjas-Howard J, Voysey M, Drysdale SB, Andrews N, Watson CH, Whitaker HJ.   +7 more
europepmc   +1 more source

Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. [PDF]

BMJ Open
Masukume G, McMorrow A, Dawood I, Rafdhy K, O'Brien F, Desmond C, O'Connell D, Murphy B, Ronan E, Purtill H, Philip RK.   +10 more
europepmc   +1 more source

Correction: Factors Associated With Newborn Nirsevimab Administration in Los Angeles County During the 2024 Respiratory Syncytial Virus Season. [PDF]

J Pediatric Infect Dis Soc
europepmc   +1 more source

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]

Pediatr Pulmonol
Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK.   +4 more
europepmc   +1 more source

Genomic evolution and minority variant dynamics of RSV during the first season of nirsevimab implementation in Italy (2024-5). [PDF]

Virus Evol
Romano G, Campagna R, Ferrari G, Pitrolo AMG, Turriziani O, Fracella M, Coratti E, Cinti L, Roberto P, Petrarca L, Nenna R, Midulla F, Bonetti A, Licari A, Piralla A, Antonelli G, Baldanti F, Pierangeli A.   +17 more
europepmc   +1 more source

Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. [PDF]

Pediatrics
Rostad CA, Healy CM, Nayak JL, Parameswaran L, Creech CB, Martin JM, Brady RC, Jones-Beatty K, Badell M, Eppes C, Quinn M, Mulligan M, Rolsma SL, Rick AM, Forde B, Avadhanula V, Piedra PA, Telu K, Kunwar PS, Mu J, Gao F, Pasetti MF, Flach B, Posavad CM, Miedema J, Piper JM, Kim S, Beresnev T, Cardemil C, Campbell JD, DMID 24-0003 PROMISE Study Group.   +30 more
europepmc   +1 more source

Administration Timing of Respiratory Syncytial Virus Preventatives Among Commercially Insured Populations in the United States: 2024-2025 RSV Season. [PDF]

Vaccines (Basel)
Law AW, Mayer DC, Zakeri M, Yapar N, Passarelli A, Baser O, MacDonald PDM.   +6 more
europepmc   +1 more source

RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness. [PDF]

Hum Vaccin Immunother
Oliva IO, Oliveira CR.
europepmc   +1 more source